248 results on '"Cassinerio, Elena"'
Search Results
2. Effects on hearing after long-term use of iron chelators in beta-thalassemia: Over twenty years of longitudinal follow-up
3. Luspatercept for the treatment of anaemia in non-transfusion-dependent β-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial
4. Management of chronic patients during the COVID-19 pandemic: the experience of a referral center for rare hematological disorders in the hardest-hit region in Italy
5. Effects on hearing after long-term use of iron chelators in beta-thalassemia: Over twenty years of longitudinal follow-up
6. Oocyte quality in women with thalassaemia major: insights from IVF cycles
7. Disorders of Hemoglobin Synthesis: Pathophysiology and Diagnostic Evaluation
8. Low-dose Synachten test with measurement of salivary cortisol in adult patients with β-thalassemia major
9. Reply to “Hepatocellular carcinoma in thalassemia and other hemoglobinopathies”
10. Ferric Carboxymaltose for Long-Term Correction of Iron Deficiency Anemia in the Emergency Department
11. Incidence of cancer and related deaths in hemoglobinopathies: A follow‐up of 4631 patients between 1970 and 2021
12. Luspatercept for the treatment of anaemia in non-transfusion-dependent β-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial
13. Myocardial deformation in iron overload cardiomyopathy: speckle tracking imaging in a beta-thalassemia major population
14. The role of hypoxia and inflammation in the regulation of iron metabolism and erythropoiesis in COVID‐19: The IRONCOVID study
15. Validity of β-d-glucosidase activity measured in dried blood samples for detection of potential Gaucher disease patients
16. Bone turnover and mineral density in adult thalassemic patients: relationships with growth hormone secretory status and circulating somatomedins
17. Splenomegaly: Dare to think rare
18. Pulmonary dysfunction in thalassaemia major: is there any relationship with body iron stores?
19. Incidence of cancer and related deaths in hemoglobinopathies: A follow‐up of 4631 patients between 1970 and 2021.
20. Migalastat Treatment in a Kidney-Transplanted Patient with Fabry Disease and N215S Mutation: The First Case Report
21. Hemoglobinopathies and Cancer: Preliminary Results of an Italian Multicenter Experience
22. Muscular de‐conditioning and reduced cardiac inotropism due to iron deposition reduce exercise tolerance in beta thalassemia major
23. Hepatocellular carcinoma in thalassaemia: an update of the Italian Registry
24. Cardiac iron removal and functional cardiac improvement by different iron chelation regimens in thalassemia major patients
25. Psychosocial aspects and psychiatric disorders in young adult with thalassemia major
26. Liver steatosis is highly prevalent and is associated with metabolic risk factors and liver fibrosis in adult patients with type 1 Gaucher disease
27. Risk factors for endocrine complications in transfusion-dependent thalassemia patients on chelation therapy with deferasirox: a risk assessment study from a multi-center nation-wide cohort
28. Liver steatosis is highly prevalent and is associated with metabolic risk factors and liver fibrosis in adult patients with type 1 Gaucher disease
29. High-Risk Population Screening for Gaucher Disease: Final Results and Key Learnings from an Italian Multicenter Observational Study
30. Clinical management of cardiovascular complications in patients with thalassaemia major: a large observational multicenter study
31. A holistic approach to iron chelation therapy in transfusion‐dependent thalassemia patients with serum ferritin below 500 μg/L
32. Reproductive health issues in female patients with beta-thalassaemia major: a narrative literature review
33. Unexpected Genotype in a Non-Transfusion Dependent Thalassemia Family
34. Transient elastography in the assessment of liver fibrosis in adult thalassemia patients
35. Iron Chelation and Ferritin below 500 Mcg/L in Transfusion Dependent Thalassemia: Beyond the Limits of Clinical Trials
36. Evaluation of in Vitro Macrophage Characterization in Gaucher Type 1 (GD1) Patients
37. Unusual Severe Development of Common B Lymphoblastic Leukemia in Gaucher Disease Type I
38. Isolated office hypertension: A 3-year follow-up study
39. Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: results from a phase 2a study
40. Home-based service for enzyme replacement therapy in lysosomal storage disorders: patient reported outcomes
41. Predicting the probability of Gaucher disease in subjects with splenomegaly and thrombocytopenia.
42. Prevalence and predictors of liver fibrosis evaluated by vibration controlled transient elastography in type 1 Gaucher disease
43. Role of T1 mapping as a complementary tool to T2* for non-invasive cardiac iron overload assessment
44. Finding and Treating Gaucher Disease Type 1 – The Role of the Haematologist
45. Efficacy and Safety of Ruxolitinib in Regularly Transfused Patients with Thalassemia: Results from Single-Arm, Multicenter, Phase 2a Truth Study
46. Adrenal insufficiency: An emerging challenge in thalassemia?
47. The role of cardiac magnetic resonance in assessing the cardiac involvement in Gaucher type 1 patients
48. The Role of Trabecular Bone Score and Hip Geometry in Thalassemia Major: A Neural Network Analysis
49. Plerixafor and G-CSF combination mobilizes hematopoietic stem and progenitors cells with a distinct transcriptional profile and a reduced in vivo homing capacity compared to plerixafor alone
50. Human CD34+ Cells from Different Sources Disclose a Specific Stemness Signature
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.